Characterization of bone metastases in patients with renal cell cancer

BJU International

Volumn 93, Issue 9, 2004, Pages 1237-1240

  Adiga, G U ^a   Dutcher, J P ^a,b   Larkin, M ^a   Garl, S ^a   Koo, J ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Saint Vincents Comprehensive Cancer Center   (United States)

Author keywords

Bone metastases; Interleukin 2; Pain; Renal cell carcinoma; Treatment

Indexed keywords

ALKALINE PHOSPHATASE; INTERLEUKIN 2; ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; BONE LESION; BONE METASTASIS; BONE PAIN; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; KIDNEY CARCINOMA; MALE; MORBIDITY; PRIORITY JOURNAL; BONE DISEASE; BONE TUMOR; KIDNEY TUMOR; METASTASIS; MIDDLE AGED; PAIN;

ADULT; AGED; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BONE DISEASES; BONE NEOPLASMS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PAIN;

EID: 2942700325     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.04849.x     Document Type: Article

References (25)

1. Lipton A. Effects of renal cell carcinoma on the skeleton. In Perry MC ed. American Society of Clinical Oncology 2002 Educational Book. Alexandria: ASCO, 2002: 633-4
2. Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. N Engl J Med 1996; 335: 865-75
3. Mani S, Todd MB, Katz K, Poo WJ. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 1995; 154: 35-40
4. Jungwirth A, Schally AV, Pinski J, Groot K, Armatis P, Halmos G. Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. Proc Natl Acad Sci USA 1997; 94: 5810-3
5. Althausen P, Althausen A, Jennings LC, Mankin HJ. Prognostic factors and surgical treatment of Osseous metastases secondary to renal cell carcinoma. Cancer 1997; 80: 1103-9
6. Koga S, Tsuda S, Nishikido M et al. The diagnostic value of bone scan in patients with renal cell carcinoma. J Urol 2001; 166: 2126-8
7. Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun A. Sarcomatoid renal cell carcinoma. Biologic behaviour, prognosis and response to combined surgical resection and immunotherapy. J Clin Oncol 1999; 17: 523-8
8. Aoki J, Yamamoto I, Hino M et al. Osteoclast-mediated osteolysis in bone metastasis from renal cell carcinoma. Cancer 1988; 62: 98-104
9. Kollender Y, Bickels J, Price WM et al. Metastatic renal cell carcinoma of bone: Indications and technique of surgical intervention. J Urol 2000; 164: 1505-8
10. Mundy GR. Advances in the biology and treatment of metastatic bone disease. In Perry MC ed. American Society of Clinical Oncology 2001 Educational Book. Alexandria: ASCO, 2001: 164-72
11. Coleman RE. Bone metastases from breast cancer and other solid tumors. In Perry MC ed. American Society of Clinical Oncology 2001 Educational Book. Alexandria: ASCO, 2001: 152-63
12. Dutcher JP, Atkins M, Fisher R et al. Interleukin-2 based therapy for metastatic renal cell cancer: The Cytokine Working Group experience, 1989-97. Cancer J Sci Am 1997; 3 (Suppl. 1): S73-578
13. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM. Effect of Cytokine therapy of survival of patients with advanced renal cell carcinoma. J Clin Oncol 2000; 18: 1928-35
14. Fisher RI, Rosenberg SA, Fyte G. Long term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000; 6: S55-S57
15. Frank W, Stuhldreher D, Saffrin R, Shott S, Guinan P. Stage IV renal cell carcinoma. J Urol 1994; 152: 1998-9
16. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-40
17. Berenson JR. Biology and biophosphonate therapy in myeloma and novel approaches to metastatic bone disease. In Perry MC ed. American Society of Clinical Oncology 2001 Educational Book. Alexandria: ASCO, 2001: 142-50
18. Paule B. Interleukin-6 and bone metastasis of renal cancer: molecular bases and therapeutic implication. Prog Urol 2001; 11: 368-75
19. Steiner T, Junker U, Wunderlich H, Schubert J. Are renal cell carcinoma cells able to modulate the cytotoxic effect of tumor infiltrating lymphocytes by secretion of interleukin-6? Anticancer Res 1999; 19: 1533-6
20. Tokuda H, Kozawa O, Harada A, Uematsu T. Tiludronate inhibits interleukin-6 synthesis in osteoblasts. inhibition of phospholipase D activation in MC3T3-E1 cells. J Cell Biochem 1998; 69: 252-9
21. Terpos E, Palermos J, Tsionos K et al. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma. Eur J Haematol 2000; 65: 331-6
22. Walther MM, Patel B, Choyke PL et al. Hypercalcemia in patients with metastatic renal cell carcinoma. Effect of nephrectomy and metabolic evaluation. J Urol 1997; 158: 733-9
23. Ueno M, Akita M, Ban SI et al. Production of parathyroid hormone-related protein in two new cell lines of renal cell carcinoma. Int J Urol 2001; 8: 549-56
24. Fahn HJ, Lee YH, Chen MT, Huang JK, Chen KK, Chang LS. The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma. J Urol 1991; 145: 248-50
25. Seaman E, Goluboff ET, Ross S, Sawezuk IS. Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma. Urology 1996; 48: 692-5